PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).

Save

Report Abuse

Description

This prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.

Targeted Conditions

Study Overview

Start Date
October 27, 2022
Completion Date
May 1, 2025
Enrollment
200
Date Posted
November 2, 2022
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
CHU de Liège
Liège 4000, Belgium

Eligibility

Minimum Age (years)
18
Eligibility Criteria
Inclusion Criteria:

o All stages of NSCLC

Stage III-IV NSCLC eligible for ICI treatment
18 years or older; non pregnant women
in stage III-IV: no previous ICI and before ICI (mono- or combination therapy) initiation
Signed informed consent
Clinical, biological and radiological evaluation at the CHU de Liège for at least 6 months following treatment initiation

Exclusion Criteria:

Probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors)
Inclusion in a clinical study contraindicating the enrolment in the PROTEON study

Study Contact Info

Study Contact Name
Anne Sibille, MD; Aurore Cue Alvarez
Study Contact Phone

Contact Listings Owner Form

PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC). 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
NCTid (if applicable)
NCT05602259